logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Metastatic Nonsmall Cell Lung Cancer

    Medications for Metastatic Nonsmall Cell Lung Cancer

    FiltersReset Filters
    22 results

    • alunbrig

      (brigatinib)
      Takeda Pharmaceuticals America, Inc.
      Usage: ALUNBRIG is indicated for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC), confirmed by an FDA-approved test.

    • braftovi

      (Encorafenib)
      Array BioPharma Inc.
      Usage: BRAFTOVI is indicated for the treatment of unresectable or metastatic melanoma, metastatic colorectal cancer, and metastatic non-small cell lung cancer, all positive for BRAF V600E or V600K mutations. These treatments require combination therapies and FDA-approved testing for mutation detection. Not for wild-type BRAF cancers.

    • cyramza

      (ramucirumab)
      Eli Lilly and Company
      Usage: CYRAMZA is indicated for treating advanced or metastatic gastric/gastro-esophageal junction cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and hepatocellular carcinoma in specific patient populations following prior treatments with chemotherapy or targeted therapies. It can be used alone or in combination with other agents.

    • gavreto

      (Pralsetinib)
      Rigel Pharmaceuticals, Inc.
      Usage: GAVRETO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and for adult and pediatric patients aged 12 and older with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy and who are radioactive iodine-refractory.

    • imjudo

      (tremelimumab)
      AstraZeneca Pharmaceuticals LP
      Usage: IMJUDO is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also used with durvalumab and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer who lack sensitizing EGFR mutations or ALK genomic aberrations.

    • lazcluze

      (lazertinib)
      Janssen Biotech, Inc.
      Usage: LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations (exon 19 deletions or exon 21 L858R) as determined by an FDA-approved test.

    • lorbrena

      (lorlatinib)
      Pfizer Laboratories Div Pfizer Inc
      Usage: LORBRENA® is indicated for adults with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive, as determined by an FDA-approved test.

    • mekinist

      (trametinib)
      Novartis Pharmaceuticals Corporation
      Usage: MEKINIST is indicated for treating unresectable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC), locally advanced or metastatic anaplastic thyroid cancer, unresectable or metastatic solid tumors, and low-grade glioma with BRAF V600E/K mutations, in combination with dabrafenib, as per FDA-approved tests.

    • mektovi

      (BINIMETINIB)
      Array BioPharma Inc.
      Usage: MEKTOVI is indicated, in combination with encorafenib, for treating unresectable or metastatic melanoma and metastatic non-small cell lung cancer (NSCLC) in adult patients with BRAF V600E or V600K mutations, as identified by FDA-approved testing.

    • opdivo

      (nivolumab)
      E.R. Squibb & Sons, L.L.C.
      Usage: OPDIVO is indicated for the treatment of various cancers, including unresectable/metastatic melanoma, neoadjuvant and adjuvant non-small cell lung cancer, metastatic non-small cell lung cancer, malignant pleural mesothelioma, advanced renal cell carcinoma, classical Hodgkin lymphoma, and others. It is used in different combinations and settings based on the cancer type.